Compass Therapeutics (CMPX) Net Cash Flow (2018 - 2026)

Compass Therapeutics has disclosed Net Cash Flow across 9 years of filings, most recently posting $24.5 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $24.5 million, up 1107.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.1 million (down 18.73% YoY), and the FY2025 annual result was -$12.8 million, down 166.68% from the prior year.
• Net Cash Flow came in at $24.5 million for Q1 2026 at Compass Therapeutics, up from -$15.6 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $24.5 million in Q1 2026 to a low of -$110.1 million in Q2 2022.
• The 5-year median for Net Cash Flow is -$4.3 million (2024), against an average of -$5.3 million.
• Across the five-year window, Net Cash Flow plunged 1206.85% in 2022 and soared 1107.19% in 2026, its largest moves.
• Compass Therapeutics' Net Cash Flow stood at $18.5 million in 2022, then tumbled by 133.57% to -$6.2 million in 2023, then soared by 198.64% to $6.1 million in 2024, then plunged by 354.65% to -$15.6 million in 2025, then soared by 257.52% to $24.5 million in 2026.
• The last three Net Cash Flow figures came in at $24.5 million (Q1 2026), -$15.6 million (Q4 2025), and $23.4 million (Q3 2025), per Business Quant data.